Design Therapeutics (NASDAQ:DSGN – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02, Yahoo Finance reports.
Design Therapeutics Price Performance
Shares of DSGN traded down $0.16 during trading hours on Wednesday, hitting $4.05. The stock had a trading volume of 28,077 shares, compared to its average volume of 237,739. The firm has a market capitalization of $228.80 million, a PE ratio of -3.88 and a beta of 1.83. Design Therapeutics has a 12 month low of $1.94 and a 12 month high of $7.83. The stock has a fifty day moving average price of $3.99 and a 200 day moving average price of $3.55.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 target price on shares of Design Therapeutics in a report on Tuesday. Piper Sandler raised Design Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $6.00 to $12.00 in a research report on Tuesday, May 7th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Design Therapeutics has a consensus rating of “Hold” and a consensus price target of $6.60.
Design Therapeutics Company Profile
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Recommended Stories
- Five stocks we like better than Design Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Super Micro Computers Splits Stock: Is This the Time to Buy?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Nuclear Power Giant’s Shares Jump on Raised Full-Year Guidance
- What Are Trending Stocks? Trending Stocks Explained
- Airbnb Stock: Key Drivers Indicate Bright Future Despite Sell-Off
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.